Korro Bio (KRRO) Q2 2026 earnings summary

Executive summary

• Focused on RNA-editing oligonucleotide (REO) therapies for rare and prevalent diseases using the OPERA platform, with lead programs KRRO-121 (hyperammonemia/UCD/HE) and KRRO-111 (AATD) advancing in preclinical and early development.

• Advanced KRRO-121 toward first-in-human clinical trials for hyperammonemia, with regulatory approval and trial initiation expected in the second half of 2026.

• EMA granted orphan drug designation for KRRO-121 targeting urea cycle disorders.

• Nominated KRRO-111 as a development candidate for AATD, showing strong preclinical efficacy.

• Novo Nordisk collaboration paused for 12 months as of November 2025, impacting near-term collaboration revenue.

Financial highlights

• No product sales; collaboration revenue was $0.0M for Q2 and H1 2026, down from $1.5M and $4.0M in Q2 and H1 2025, respectively, due to the Novo Nordisk pause.

• Net loss for Q2 2026 was $18.9M (vs. $25.8M Q2 2025); H1 2026 net loss was $38.5M (vs. $49.2M H1 2025).

• Operating expenses for H1 2026 were $40.5M, down from $56.2M in H1 2025, reflecting lower R&D and G&A costs after workforce reductions and program terminations.

• Cash, cash equivalents, and marketable securities totaled $137.9M as of June 30, 2026, up from $85.2M at year-end 2025.

• Raised $85.0M gross in March 2026 PIPE and $5.1M via ATM program in January 2026.

Outlook and guidance

• Cash runway expected to fund operations into the second half of 2028, supporting multiple RNA editing programs.

• Anticipates continued operating losses and negative cash flows as R&D and clinical activities expand.

• Plans to initiate KRRO-121 clinical trial and nominate a third GalNAc-conjugated program in 2H 2026.